NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE: ENZ) today reported that scientists from its Enzo Therapeutics group presented a podium session entitled “The Presence of Sulfated Tyrosine In Scelerostin and Dkk1 Ligands and its Effect on Wnt Signaling” at the WNT 2011 conference in Los Angeles Thursday, June 30, 2011. “Our scientific team has identified a new target on a key modulator of the Wnt system that not only allows for development of novel antibodies for the modulation of this important pathway, but it has also identified a small peptide that can accomplish the same modulation without the need for antibodies,” said Dr. Elazar Rabbani, CEO of Enzo Biochem.
